Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

Ensuring patient access to essential medicines while minimizing harmful use: a revised World Health Organization tool to improve national drug control policy.

Gilson AM, Maurer MA, Ryan KM, Skemp-Brown M, Husain A, Cleary JF.

J Pain Palliat Care Pharmacother. 2011;25(3):246-51. doi: 10.3109/15360288.2011.599485.

PMID:
21882978
2.

Re: Ensuring patient access to essential medicines while minimizing harmful use: a revised World Health Organization tool to improve national drug control policy. Letter to the editor.

Radbruch L, Jünger S, Mantel-Teeuwisse A, Gilson A, Cleary J, Payne S, Scholten W.

J Pain Palliat Care Pharmacother. 2012 Jun;26(2):200-1. doi: 10.3109/15360288.2012.676614. No abstract available.

PMID:
22616835
3.

Do international model drug control laws provide for drug availability?

University of Wisconsin Pain & Policy Studies Group..

J Pain Palliat Care Pharmacother. 2009;23(2):145-52. doi: 10.1080/15360280902900729.

PMID:
19492215
4.

Drug policy: making effective drugs available without bankrupting the healthcare system.

Laupacis A, Anderson G, O'Brien B.

Healthc Pap. 2002;3(1):12-30. Review.

PMID:
12811107
6.

An analysis of China's national essential medicines policy.

Guan X, Liang H, Xue Y, Shi L.

J Public Health Policy. 2011 Aug;32(3):305-19. doi: 10.1057/jphp.2011.34.

PMID:
21614030
7.

Rare essentials: drugs for rare diseases as essential medicines.

Stolk P, Willemen MJ, Leufkens HG.

Bull World Health Organ. 2006 Sep;84(9):745-51.

8.

The essential drugs concept is needed now more than ever.

Smith MK, Tickell S.

Trans R Soc Trop Med Hyg. 2003 Jan-Feb;97(1):2-5.

PMID:
12886792
9.

Access to essential drugs in Guyana: a public health challenge.

Seoane-Vazquez E, Rodriguez-Monguio R.

Int J Health Plann Manage. 2010 Jan-Mar;25(1):2-16. doi: 10.1002/hpm.949.

PMID:
18536003
10.

The morally uncomfortable global drug gap.

Cohen-Kohler JC.

Clin Pharmacol Ther. 2007 Nov;82(5):610-4.

PMID:
17898710
11.

[National pharmaceutical policy in Colombia and social security reform: access and rational use of medicines].

Mejia Restrepo S, Velez Arango AL, Buritica Arboleda OC, Arango Mejia MC, Rio Gomez JA.

Cad Saude Publica. 2002 Jul-Aug;18(4):1025-39. Spanish.

12.
13.

Global aspects of drug development.

Hoppu K, Hogerzeil HV.

Handb Exp Pharmacol. 2011;205:353-72. doi: 10.1007/978-3-642-20195-0_18.

PMID:
21882121
14.

[Adherence to essential medicines in cities from three Brazilian states].

Dal Pizzol Tda S, Trevisol DJ, Heineck I, Flores LM, Camargo AL, Köenig A, Torres IL, Kadri MC, Monreal MT, Melo AM, Ferreira MB.

Cad Saude Publica. 2010 Apr;26(4):827-36. Portuguese.

15.

Developing nations and the compulsory license: maximizing access to essential medicines while minimizing investment side effects.

Bird RC.

J Law Med Ethics. 2009 Summer;37(2):209-21. doi: 10.1111/j.1748-720X.2009.00366.x.

PMID:
19493067
16.

Do national medicinal drug policies and essential drug programs improve drug use?: a review of experiences in developing countries.

Ratanawijitrasin S, Soumerai SB, Weerasuriya K.

Soc Sci Med. 2001 Oct;53(7):831-44.

PMID:
11522132
17.

Twenty-five years of essential medicines.

Quick JD, Hogerzeil HV, Velasquez G, Rago L.

Bull World Health Organ. 2002;80(11):913-4. No abstract available.

18.

Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative.

Cherny NI, Baselga J, de Conno F, Radbruch L.

Ann Oncol. 2010 Mar;21(3):615-26. doi: 10.1093/annonc/mdp581.

PMID:
20176694
19.

Essential medicines twenty-five years on: closing the access gap.

Quick JD.

Health Policy Plan. 2003 Mar;18(1):1-3. No abstract available.

PMID:
12582103
20.

What essential medicines for children are on the shelf?

Robertson J, Forte G, Trapsida JM, Hill S.

Bull World Health Organ. 2009 Mar;87(3):231-7.

Supplemental Content

Support Center